Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, Daniel A, Tuyishimire, Bonifride, Ahuja, Neera, Beigel, John H, Beresnev, Tatiana, Cantos, Valeria D, Castro, Jose G, Cohen, Stuart H, Cross, Kaitlyn, Dodd, Lori E, Erdmann, Nathan, Fung, Monica, Ghazaryan, Varduhi, George, Sarah L, Grimes, Kevin A, Hynes, Noreen A, Julian, Kathleen G, Kandiah, Sheetal, Kim, Hannah Jang, Levine, Corri B, Lindholm, David A, Lye, David C, Maves, Ryan C, Oh, Myoung-don, Paules, Catharine, Rapaka, Rekha R, Short, Willam R, Tomashek, Kay M, Wolfe, Cameron R, Kalil, Andre C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191442/
https://www.ncbi.nlm.nih.gov/pubmed/37206623
http://dx.doi.org/10.1093/ofid/ofad205
_version_ 1785043462910902272
author Sweeney, Daniel A
Tuyishimire, Bonifride
Ahuja, Neera
Beigel, John H
Beresnev, Tatiana
Cantos, Valeria D
Castro, Jose G
Cohen, Stuart H
Cross, Kaitlyn
Dodd, Lori E
Erdmann, Nathan
Fung, Monica
Ghazaryan, Varduhi
George, Sarah L
Grimes, Kevin A
Hynes, Noreen A
Julian, Kathleen G
Kandiah, Sheetal
Kim, Hannah Jang
Levine, Corri B
Lindholm, David A
Lye, David C
Maves, Ryan C
Oh, Myoung-don
Paules, Catharine
Rapaka, Rekha R
Short, Willam R
Tomashek, Kay M
Wolfe, Cameron R
Kalil, Andre C
author_facet Sweeney, Daniel A
Tuyishimire, Bonifride
Ahuja, Neera
Beigel, John H
Beresnev, Tatiana
Cantos, Valeria D
Castro, Jose G
Cohen, Stuart H
Cross, Kaitlyn
Dodd, Lori E
Erdmann, Nathan
Fung, Monica
Ghazaryan, Varduhi
George, Sarah L
Grimes, Kevin A
Hynes, Noreen A
Julian, Kathleen G
Kandiah, Sheetal
Kim, Hannah Jang
Levine, Corri B
Lindholm, David A
Lye, David C
Maves, Ryan C
Oh, Myoung-don
Paules, Catharine
Rapaka, Rekha R
Short, Willam R
Tomashek, Kay M
Wolfe, Cameron R
Kalil, Andre C
author_sort Sweeney, Daniel A
collection PubMed
description We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
format Online
Article
Text
id pubmed-10191442
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101914422023-05-18 Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections Sweeney, Daniel A Tuyishimire, Bonifride Ahuja, Neera Beigel, John H Beresnev, Tatiana Cantos, Valeria D Castro, Jose G Cohen, Stuart H Cross, Kaitlyn Dodd, Lori E Erdmann, Nathan Fung, Monica Ghazaryan, Varduhi George, Sarah L Grimes, Kevin A Hynes, Noreen A Julian, Kathleen G Kandiah, Sheetal Kim, Hannah Jang Levine, Corri B Lindholm, David A Lye, David C Maves, Ryan C Oh, Myoung-don Paules, Catharine Rapaka, Rekha R Short, Willam R Tomashek, Kay M Wolfe, Cameron R Kalil, Andre C Open Forum Infect Dis Brief Report We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019. Oxford University Press 2023-04-19 /pmc/articles/PMC10191442/ /pubmed/37206623 http://dx.doi.org/10.1093/ofid/ofad205 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Sweeney, Daniel A
Tuyishimire, Bonifride
Ahuja, Neera
Beigel, John H
Beresnev, Tatiana
Cantos, Valeria D
Castro, Jose G
Cohen, Stuart H
Cross, Kaitlyn
Dodd, Lori E
Erdmann, Nathan
Fung, Monica
Ghazaryan, Varduhi
George, Sarah L
Grimes, Kevin A
Hynes, Noreen A
Julian, Kathleen G
Kandiah, Sheetal
Kim, Hannah Jang
Levine, Corri B
Lindholm, David A
Lye, David C
Maves, Ryan C
Oh, Myoung-don
Paules, Catharine
Rapaka, Rekha R
Short, Willam R
Tomashek, Kay M
Wolfe, Cameron R
Kalil, Andre C
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title_full Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title_fullStr Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title_full_unstemmed Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title_short Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
title_sort baricitinib treatment of coronavirus disease 2019 is associated with a reduction in secondary infections
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191442/
https://www.ncbi.nlm.nih.gov/pubmed/37206623
http://dx.doi.org/10.1093/ofid/ofad205
work_keys_str_mv AT sweeneydaniela baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT tuyishimirebonifride baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT ahujaneera baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT beigeljohnh baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT beresnevtatiana baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT cantosvaleriad baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT castrojoseg baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT cohenstuarth baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT crosskaitlyn baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT doddlorie baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT erdmannnathan baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT fungmonica baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT ghazaryanvarduhi baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT georgesarahl baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT grimeskevina baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT hynesnoreena baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT juliankathleeng baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT kandiahsheetal baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT kimhannahjang baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT levinecorrib baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT lindholmdavida baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT lyedavidc baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT mavesryanc baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT ohmyoungdon baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT paulescatharine baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT rapakarekhar baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT shortwillamr baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT tomashekkaym baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT wolfecameronr baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections
AT kalilandrec baricitinibtreatmentofcoronavirusdisease2019isassociatedwithareductioninsecondaryinfections

Ejemplares similares